CoChat

The role of biomarkers in personalized immunotherapy

Open access
Sankar, Kamya, Ye, Jing Christine, Li, Zihai, Zheng, Lei, Song, Wenru, Hu-Lieskovan, Siwen · 2022 · Biomarker Research

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Abstract

Background: Immune checkpoint inhibitors have revolutionized cancer therapeutic paradigm and substantially improved the survival of patients with advanced malignancies. However, a significant limitation is the wide variability in clinical response. Main text: Several biomarkers have been evaluated in prior and ongoing clinical trials to investigate their prognostic and predictive role of patient response, nonetheless, most have not been comprehensively incorporated into clinical practice. We reviewed published data regarding biomarkers that have been approved by the United States Food and Drug Administration as well as experimental tissue and peripheral blood biomarkers currently under investigation. We further discuss the role of current biomarkers to predict response and response to immune checkpoint inhibitors and the promise of combination biomarker strategies. Finally, we discuss ideal biomarker characteristics, and novel platforms for clinical trial design including enrichment and stratification strategies, all of which are exciting and dynamic to advance the field of precision immuno-oncology. Conclusion: Incorporation and standardization of strategies to guide selection of combination biomarker approaches will facilitate expansion of the clinical benefit of immune checkpoint inhibitor therapy to appropriate subsets of cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40364-022-00378-0

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Timeline of biomarker test approvals by the U.S. Food and Drug Administration
Fig. 1 Timeline of biomarker test approvals by the U.S. Food and Drug AdministrationCC BY · PubMed Central
Fig. 2 Using dual biomarker approaches to group potential resistant mechanisms for effective combination strategies
Fig. 2 Using dual biomarker approaches to group potential resistant mechanisms for effective combination strategiesCC BY · PubMed Central
Fig. 3 The incorporation of prospective biomarkers in immunotherapy clinical trials
Fig. 3 The incorporation of prospective biomarkers in immunotherapy clinical trialsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 107 references

Cited by

See all 111

Metadata

Authors
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S.
Affiliations
  • University of Michigan (US)
  • The Ohio State University (US)
  • Johns Hopkins University (US)
Venue
Biomarker Research
Published
2022-05-18
Volume
10
Issue
1
Pages
32-32
ISSN
2050-7771 (ISSN-L)
OpenAlex
W4280540063
Cited by
111
References
107
Citations by year
2026: 20 · 2025: 23 · 2024: 43 · 2023: 17 · 2022: 8
FWCI
2.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomarker Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Michigan Library
Funders
National Cancer Institute (P50CA062924, P01CA247886, R01CA197296)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
immune checkpoint inhibitors, biomarkers, personalized immunotherapy, predictive biomarkers, prognostic factors, treatment response prediction, combination biomarkers, biomarker standardization, clinical trial enrichment, patient stratification, precision immuno-oncology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of biomarkers in personalized immunotherapy. https://app.cochat.ai/papers/10.1186/s40364-022-00378-0
The paper
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022). The role of biomarkers in personalized immunotherapy. Biomarker Research. https://doi.org/10.1186/s40364-022-00378-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.